Navigation Links
BioMarin Announces First Quarter 2011 Financial Results
Date:4/28/2011

ause it provides additional information regarding the performance of BioMarin's core ongoing business, Naglazyme, Kuvan, Aldurazyme and Firdapse and development of its pipeline.  By providing information about both the overall GAAP financial performance and the non-GAAP measures that focus on continuing operations, the company believes that the additional information enhances investors' overall understanding of the company's business and prospects for the future.  Further, the company uses both the GAAP and the non-GAAP results and expectations internally for its operating, budgeting and financial planning purposes and uses the adjusted EBITDA methodology in establishing corporate goals for internal compensation programs.

Diluted Earnings Per Share Calculation As of March 31, 2011 and March 31, 2010, the shares related to our outstanding convertible debt are 19.1 million and 26.3 million, respectively. The calculation of non-GAAP adjusted EBITDA diluted earnings per share for the quarter ended March 31, 2011 and March 31, 2010 includes the 19.1 million shares and the 10.3 million shares, respectively, related to the company's convertible debt, as their impact is considered dilutive.

Conference Call DetailsBioMarin will host a conference call and webcast to discuss first quarter 2011 financial results today, Thursday, April 28, at 5:00 p.m. ET. This event can be accessed on the investor section of the BioMarin website at www.BMRN.com.

Date: April 28, 2011
Time: 5:00 p.m. ET
U.S. / Canada Dial-in Number:  888.396.2386
International Dial-in Number:  617.847.8712
Participant Code: 42725170
Replay Dial-in Number: 888.286.8010
Replay International Dial-in Number: 617.801.6888
Replay Code: 56138656

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio compris
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. BioMarin Announces FDA Approval for Kuvan
3. BioMarin Initiates Phase 1 Clinical Study of PEG-PAL in PKU
4. BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease
5. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
6. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
7. BioMarin Acquires Huxley Pharmaceuticals, Inc.
8. BioMarin to Present at the Oppenheimer Healthcare Conference
9. BioMarin Announces Third Quarter 2009 Financial Results
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced the ... common stock and warrants at a price of $10,000 ... to deducting underwriting discounts and commissions and offering expenses ... immediately separable and will be issued separately.  The shares ... The NASDAQ Stock Market under the ticker symbol "WGBS" ...
(Date:8/21/2014)... 21, 2014 Nektar Therapeutics (NASDAQ: ... announced positive results from its Phase 3 pivotal ... half-life recombinant factor VIII (rFVIII) treatment for hemophilia ... met its primary endpoint in reducing annualized bleed ... the on-demand arm. Top-line results from ...
(Date:8/21/2014)... 2014 /CNW/ - Eisai Limited is pleased to support the ... comic book available in Canada . The ... to educate children and their parents about epilepsy, the most ... more than 300,000 Canadians. Eisai is guided by a corporate ... which the patient is central – there was a need ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... 22, 2011     ... catch up   with   their urban counterparts in adopting technology ...   data spill shows risk of online health records . ... IT and its current challenges? Ambitious national healthcare IT programmes and ...
... Aug. 20, 2011 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: ... leading China-based biotechnology company focused on researching, developing, ... the annual general meeting of shareholders of 3SBio ... at 10:00 a.m., Shenyang time, at our executive ...
Cached Medicine Technology:Innovations in E-Health & Informatics Europe: The Need for a European EHealth Strategy 23SBio Inc. to Hold 2011 Annual General Meeting on September 20, 2011 2
(Date:8/23/2014)... The report “Polycarbonate Resin Market by ... 2018” defines and segments the global polycarbonate resin ... revenue and consumption. It also identifies driving and ... with analysis of trends, opportunities, burning issues, winning ... revenues are forecasted on the basis of major ...
(Date:8/23/2014)... 2014 Having been in the dental field ... Arlington, Texas, saw a need for an effective way to ... I came up with the idea for my design," she ... way for a user to clean the mouth without a ... items. It also helps avoid plaque buildup and maintains proper ...
(Date:8/23/2014)... CA (PRWEB) August 23, 2014 ... trading system created by Greg Marks has been generating ... earlier this month. The commotion surrounding the new product ... an investigative review. , “In recent years ... trading software systems, commonly referred to as robots or ...
(Date:8/23/2014)... Boston, MA (PRWEB) August 23, 2014 ... now have a study aid in preparing for Food ... safety practice test by Dynamic Path. , Dynamic ... study module, which includes more than 200 review questions ... study materials are designed to cover requirements of the ...
(Date:8/23/2014)... August 23, 2014 Youth substance abuse ... It’s no different in Houston, TX. Substance abuse can ... victim to drug and alcohol dependency in higher numbers ... to beat substance abuse, but don’t know where to ... facility can be a challenge because most treatment options ...
Breaking Medicine News(10 mins):Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4Health News:Legal Insider Bot Review Examining Greg Marks’ Trading Software Released 2Health News:Food Handler Safety Certification Made Easy with Dynamic Path 2Health News:New Houston Hotline Assisting Juveniles in Locating Dependable Rehabilitation Help 2
... better prognosis, study finds , , FRIDAY, Dec. 12 (HealthDay News) ... the risk of getting breast cancer, but women who take ... risk of dying from the disease, a new study suggests. ... particular type of cancer that is easier to treat," explained ...
... Ariz., Dec. 12 Roberta Kalafut, D.O., just announced her ... to a close the worst abuses of power by the ... unjust disciplinary actions, particularly against her competitors, and stonewalling by ... , "We applaud Kalafut,s resignation," said AAPS Executive ...
... Fair Offers New Chemists and Chemical Engineers an Opportunity to ... , PRINCETON, N.J., Dec. 12 Informex ... the upcoming InformexUSA exhibition in San Francisco free of charge. ... 25 and under to learn more about the chemical technologies ...
... saw disease stabilize or improve, study shows , , ... combination of medicines designed to boost immune function ... interim results from an ongoing Mayo Clinic study. ... immunomodulatory drug called pomalidomide with dexamethasone (pom/dex) improved ...
... At its 12th annual holiday gala The,Teddy Bear ... Award to Steve,Mosko, President of Sony Pictures Television ... to children with special needs. Grammy(R),winning singer-songwriter Kenny ... of the Heart. Long standing friend and colleague ...
... YORK, Dec. 12 In his last public remarks as,the ... Lilly and Company (NYSE: LLY ), today said ... markets and regulatory environments,encourage and reward companies for the long-term, ... bench to the bedside. , ...
Cached Medicine News:Health News:HRT Users Who Get Breast Cancer Less Likely to Die 2Health News:HRT Users Who Get Breast Cancer Less Likely to Die 3Health News:AAPS Applauds the Resignation of TMB President Roberta Kalafut, Mari Robinson Should Resign Next 2Health News:Informex Invites Young Chemists to Attend InformexUSA 2Health News:Informex Invites Young Chemists to Attend InformexUSA 3Health News:Combo Therapy Helps Multiple Myeloma Patients 2Health News:The Help Group's Teddy Bear Ball Salutes Sony Pictures Television President, Steve Mosko and Features Performance by Kenny Loggins 2Health News:Lilly Chairman Taurel Says Promise of Personalized Medicine Could be Jeopardized by Short-Sighted Public Policies 2Health News:Lilly Chairman Taurel Says Promise of Personalized Medicine Could be Jeopardized by Short-Sighted Public Policies 3
... cost-effective line of compact CO2 systems available ... 30 or 40 watts combines portability ... extremely accurate laser beam, as well as ... advantageous for small operating theatres and are ...
... Applications include PhotoLightFACIAL facial skin ... vein removal. Incorporates a ... to 1200nm), multiple hand pieces ... give you the most flexibility. ...
... delivered through an ultra thin flexible 400 - ... freedom of movement when performing surgery. The ... range of handpieces. Handpieces are supplied with ... mm. Straight and angled fiber guides with ...
These are the Reusable Components (minus cannula), to be used with the VersaStep™ Plus Reposable Short System....
Medicine Products: